WA1
VRTX icon

Wimmer Associates 1’s Vertex Pharmaceuticals VRTX Stock Holding History

Wimmer Associates 1’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.56M Buy
5,733
+207
+4% +$96.5K 1.25% 20
2025
Q4 		$2.51M Buy
5,526
+71
+1% +$30.6K 1.16% 21
2025
Q3 		$2.14M Sell
5,455
-137
-2% -$57.3K 1.03% 26
2025
Q2 		$2.49M Sell
5,592
-2
-0% -$922 1.27% 20
2025
Q1 		$2.42M Sell
5,594
-11
-0.2% -$5.13K 1.27% 20
2024
Q4 		$2.26M Sell
5,605
-6
-0.1% -$2.78K 1.12% 27
2024
Q3 		$2.61M Buy
5,611
+15
+0.3% +$7.21K 1.28% 23
2024
Q2 		$2.62M Buy
5,596
+119
+2% +$51.7K 1.34% 20
2024
Q1 		$2.29M Buy
5,477
+86
+2% +$36.4K 1.2% 25
2023
Q4 		$2.19M Buy
5,391
+370
+7% +$137K 1.24% 26
2023
Q3 		$1.75M Buy
5,021
+473
+10% +$165K 1.09% 29
2023
Q2 		$1.6M Buy
4,548
+2,335
+106% +$787K 0.96% 31
2023
Q1 		$772K Buy
2,213
+69
+3% +$20.7K 0.49% 53
2022
Q4 		$619K Hold
2,144
– – 0.41% 65
2022
Q3 		$669K Buy
2,144
+61
+3% +$17.6K 0.44% 59
2022
Q2 		$587K Buy
2,083
+1,299
+166% +$348K 0.38% 64
2022
Q1 		$205K Buy
+784
New +$186K 0.11% 117

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wimmer Associates 1's VRTX Position: Q1 2026 in Review

Wimmer Associates 1 increased its Vertex Pharmaceuticals (VRTX) stake by 3.7% in Q1 2026, buying an estimated $96.5K and bringing the position to 5,733 shares worth $2.56M. The position accounts for 1.25% of the portfolio, ranked #20.

Wimmer Associates 1 first reported a position in VRTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.62M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Wimmer Associates 1 held 5,733 shares of Vertex Pharmaceuticals worth $2.56M as of Q1 2026.
  • Wimmer Associates 1 bought 207 Vertex Pharmaceuticals shares in Q1 2026, an estimated $96.5K.
  • Vertex Pharmaceuticals made up 1.25% of Wimmer Associates 1's portfolio in Q1 2026, its #20 holding.
  • Wimmer Associates 1 first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 17 quarters since.
  • Wimmer Associates 1's Vertex Pharmaceuticals position peaked at $2.62M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Wimmer Associates 1's 13F filing for Q1 2026, filed 15 May 2026.